Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Maybe this has been mentioned already, but if no - has anyone noticed DCVax is mentioned in the latest season of Industry? (season 3 episode 5). Really took me by surprise.
To my knowledge ATNM har never received a CRL letter. They haven't filed BLA either, so I don't see why you ask this question.
Are you looking at another chart than me? On the six month chart the SP has been cut in half. The last pull was BLA filing being moved from H2 23 to H1 24.
How big is the sales team and infrastructure supposedly trying to sell this in Europe compared to the organization they have in the U.S.?
By all means, the company faces a binary event now as it did in 2019 (when this article is from). However, I don't see how the article you refer to brings any information of value at the companys current situation.
I'm a novice (at best) in this, but isn't it healthy for the stock to consolidate at these keveks? The RSI on the daily was over 90 before yesterday and now it's back in the low 70's.
Cheers - I'd take a buyout. Would actually appreciate someone taking the decision of when to exit out of my hands
You say 70% accurate as to your price targets and also that 20-25 will definitely happen before year end. So what's your price target?
You don't think we'll see a run up leading to Ash?
NEW YORK, Oct. 31, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced positive top-line results from the pivotal Phase 3 trial for its lead product candidate Iomab-B. The SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) trial was conducted in patients 55 years of age or older who had active disease (relapsed or refractory AML). The SIERRA trial is a randomized, multi-center, controlled study which compared Iomab-B as a conditioning regimen prior to a Bone Marrow Transplant (BMT) versus a control arm which allowed all current means of conventional care with the intent to transplant these patients. The SIERRA trial met its primary endpoint of durable complete remission or dCR of 6 months post initial remission after a BMT in Iomab-B arm compared to conventional care arm demonstrating statistical significance p<0.0001.
Impressive how he wrote about delays due to covid more than a year in advance of the pandemic!
About to test the 50 MA on the daily. If it holds tomorrow, I'd load up more shares if I had the funds. Hopefully it'll stay in this area until earnings (looking to buy more next week with anticipated profits from another stock).
If I had to choose one stock I'd set and forget, it would be this one - diamond hands, people!
Cheers! I haven't found a source on it either, but from the chatter I've seen on different platforms july and august was the general expectation for when results would be announced.
Are there any indications as to when interim results will be released?
Apart from them reiterating estimates for covid delays (which was to be expected), I think the cc went really well. I was reassured all is on track to say the least and will look to accumulate more.
According to Webull 19,85 % of todays volume (709k) was traded at 15.00, so 140k shares.
Bought more at 15.00
Cheers. I haven't been able to follow as closely the last couple of days. Seems like I missed the latest increase in PPS (at one point 50 % in two days). That being said, you're not afraid this will be shorted down again with all the class action noise? You think we'll see a short squeeze?
Cheers! Already have a small position in PAYS, but will have a look at BABYF.
Such as?
Cheers! I thought they were referring to a new commercial agreement like the one they have with RadNet.
Based on what?
Definitely agree on Raymond James, their analyst is always first out of the gates in the Q&A. Also good to hear several ‘new’ analysts asking questions in this call.
I agree - especially with your last remark. I can understand they haven't PR'ed any of these highlights yet due to no material agreements, however I hope they understand the value in announcing every contract like the first one.
IMO this is how the company can show the market (and the shareholders) appreciation of their technology and the fact that they're actually increasing their share of the market.
I don’t know. They went public with a guided estimate increase if I remember correctly, so in a way one can argue that creates even greater expectations for earnings. I contemplated taking profits at 20 and wait for the rsi to cool off. However, now that I decided to let it play out (my average is 8), I see no reason selling now. I’m by no means experienced and I have a long perspective, and this is all jmho
RSI on the daily almost down to 30. At this point I’m thinking it would be smart to add before earnings. However, the corona hysteria has me hesitating..
When is Q4 ER and wouldn't this be a perfect time for an entry/adding to PAYS?
I share your concern about not 'getting back into the stock in time'. When looking for the report you mention from today, I can't find anything around noon. Is it the one I've linked below? If not, please share the link. Cheers!
https://www.cantechletter.com/2020/02/profound-medical-is-a-double-says-raymond-james/
So the share price has reached an all time high basically every day this month it seems and the RSI just passed 90. I have little to no experience nor skill with technical analysis, so I'll ask you fellow shareholders - isn't it plausible we'll see a correction/stagnation in the share price soon? Are any of you collecting any profit at this point and looking to get back in when things 'cool off'?
Great news. In summary PROF will save .9 million USD in interest expenses.
«Profound Medical Retires Bank Debt Ahead of Schedule
TORONTO, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today announced that it has retired its $12.5 million in principal amount loan with Canadian Imperial Bank of Commerce (“CIBC”), maturing on July 29, 2022.
“We are pleased to have repaid the CIBC loan almost 30 months ahead of schedule, resulting in total estimated net savings of approximately $0.9 million in interest payments,” commented Aaron Davidson, CFO and Senior Vice President of Corporate Development of Profound Medical. “Now, with a balance sheet strengthened by our recently completed public financing and this extinguishment of all long-term debt, we believe that we are well positioned to scale the business going forward.”
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (BPH). TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration.
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
Forward-Looking Statements
This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding its U.S. multi-center commercial agreement with RadNet; the efficacy of Profound’s technology in the treatment of prostate cancer, uterine fibroids and palliative pain treatment; Profound’s preliminary unaudited fourth quarter and full year 2019 revenues; the potential obtainment of a C-Code from CMS for TULSA-PRO®; and the success of Profound’s U.S. commercialization strategy and activities for TULSA-PRO®. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
Brilliant. Thank you for sharing, Ezzra
PROF vs PAYS
Although I believe PAYS will do well in time, I’m extremely happy I have nine shares of PROF for each PAYS share. The race between the two can hardly be called a race at the moment. GLTA
https://www.cantechletter.com/2020/01/profound-medical-gets-2020-best-pick-honours-from-raymond-james/
PROF gets "2020 Best pick" status from Raymond James. Upgraded from "outperform" to "strong buy" and price target raised from 35$ to 45$.
According to recent press release the unaudited estimate is Q4 rev 2,7 musd. Looks really promising if you ask me. Glad to be here early. GLTA
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenues & Provides TULSA-PRO® U.S. Commercialization Update
TORONTO, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today announced preliminary unaudited revenues for the fourth quarter and full year 2019, and provided an update on the early progress it is making with the commercialization of TULSA-PRO® in the United States. Profound is providing this information due to the significant lag time between planned investment community meetings to be held in connection with, among other investor events, the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, and its expected reporting of final 2019 results in March 2020.
Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenues
Profound anticipates total revenues for the fourth quarter of 2019 to be approximately $2.7 million, representing growth of 59% year-over-year and 296% sequentially over the previous quarter. For the full year 2019, the Company anticipates total revenues to be approximately $5.4 million, which compares to $2.6 million in 2018. These figures are preliminary and unaudited, and actual revenues may differ.
“The continuing roll-out of Sonalleve® in China, combined with the added traction TULSA-PRO® has been getting in international markets since the positive TACT clinical data was announced in Q2-2019, led to this significant increase in quarterly revenues,” said Arun Menawat, Profound’s CEO. “While our sales performance in the fourth quarter was a clear positive, it should be noted this was offset by the additional cash flow utilization in the period associated with becoming a Nasdaq listed company. Moving into 2020, our main focus is on executing the commercial launch of TULSA-PRO® in the United States, building on the momentum of the early activities and success reported below.”
TULSA-PRO® U.S. Commercialization Update
Multi-Site Agreement with RadNet
As reported earlier today, Profound has signed its first-ever U.S. multi-site imaging center agreement for TULSA-PRO® with RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 340 owned and/or operated outpatient imaging centers.
“We are excited that RadNet, the largest U.S. owner and operator of outpatient imaging centers, will be the first multi-site user of TULSA-PRO® under Profound’s recurring revenue-only business model, and view this as an early validation of our go-to-market strategy,” commented Dr. Menawat.
C-Code Application
In November 2019, Profound submitted its application for a Healthcare Common Procedure Coding System (HCPCS) C-Code from the Centers for Medicare & Medicaid Services (“CMS”) for the TULSA-PRO® procedure.
A C-Code is a unique temporary product code established by CMS for the Hospital Outpatient Prospective Payment System (“OPPS”) to promote the adoption of new medical technology that otherwise had no codes to facilitate payment. C-Codes are used on Medicare OPPS claims, but may also be recognized on claims from other providers or by other payment systems.
“We are accelerating our reimbursement strategy for TULSA-PRO® by pursuing both temporary and permanent CMS codes,” said Dr. Menawat. “If and when Profound receives a C-Code for TULSA-PRO®, it would provide for a 3-year period of coding and billing methodology for facility costs, where patients may only be required to personally cover the related physician fees. As for the longer term, we expect patient recruitment to begin in the first half of 2020 for planned additional trials designed to expand the body of clinical publications and enable TULSA-PRO® to qualify for a specific CPT code.”
About RadNet, Inc.
RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 340 owned and/or operated outpatient imaging centers. RadNet's core markets include California, Maryland, Delaware, New Jersey, and New York. In addition, RadNet provides radiology information technology solutions, teleradiology professional services, and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technicians, RadNet has a total of over 8,000 employees.
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities. TULSA-PRO® has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (BPH). TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration.
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
Forward-Looking Statements
This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding its U.S. multi-center commercial agreement with RadNet; the efficacy of Profound’s technology in the treatment of prostate cancer, uterine fibroids and palliative pain treatment; Profound’s preliminary unaudited fourth quarter and full year 2019 revenues; the potential obtainment of a C-Code from CMS for TULSA-PRO®; and the success of Profound’s U.S. commercialization strategy and activities for TULSA-PRO®. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
Profound Medical and RadNet Sign the First-Ever U.S. Multi-Center Commercial Agreement for TULSA-PRO®
https://finance.yahoo.com/news/profound-medical-radnet-sign-first-110210749.html
How about posting a link to it..
10 x average 3 month volume today, and what to me seems like an all time high daily volume (at least according to webull). Is there something extraordinary brewing or is it due to recent BUY ratings and edited price targets. I don't know and I'd love for any of you to weigh in. In any event I love the volume and I agree With those who describe this as a relatively unknown gem.
https://newsfilter.io/articles/zacks-analysts-set-2342-price-target-for-profound-medicl-nyseprof-fce3bf4057a19d748237fc302bb37628
Profound Medicl (NYSE:PROF) has earned an average broker rating score of 1.77 (Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating on the company.
Brokers have set a 12 month consensus price objective of $23.42 for the company and are anticipating that the company will post ($0.39) EPS for the current quarter, according to Zacks. Zacks has also assigned Profound Medicl an industry rank of 61 out of 255 based on the ratings given to related companies.
Separately, Echelon Wealth Partners reaffirmed a “buy” rating on shares of Profound Medicl in a report on Friday, November 8th.
NYSE:PROF traded up $0.22 during trading hours on Friday, reaching $8.70. 200 shares of the stock were exchanged, compared to its average volume of 4,944. Profound Medicl has a 52 week low of $3.69 and a 52 week high of $12.00.
Profound Medicl (NYSE:PROF) last released its earnings results on Thursday, November 7th. The company reported ($0.43) EPS for the quarter. The business had revenue of $0.52 million during the quarter.
I'm really surprised by todays and recent trading days. Today we even have positive News, but still we're trending downwards. Any views as to why?